FDA Clears Trial Application for FG001 in Brain Cancer

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application from FluoGuide A/S in Copenhagen, Denmark, allowing the company to move forward in the U.S. with a clinical trial of FG001 for patients with high-grade glioma, a serious form of brain cancer with limited treatment options.

FDA clears IND for FG001 in high-grade glioma

FluoGuide announced on February 20, 2026, in a news release, that the FDA informed the company it may proceed with its proposed clinical investigation of FG001. The investigational new drug, or IND, supports the initiation of the company’s first U.S. trial designed to support registration in patients with high-grade glioma.

High-grade glioma includes aggressive brain cancers such as glioblastoma. For patients with cancer facing this diagnosis, surgery is often a central part of treatment. FG001 is designed to light up cancer tissue during surgery to improve precision.

The FDA’s clearance of the IND represents a regulatory milestone for the company and marks the transition of FG001 into late-clinical development in the U.S. According to the announcement, enrollment of the first patient in the U.S. trial is expected in the second quarter of 2026.

In a statement included in the announcement, Morten Albrechtsen, CEO of FluoGuide, said the company is advancing FG001 into its planned U.S. clinical trial following the FDA review milestone.

What the FDA clearance means for patients with cancer

An investigational new drug application is required before a company can begin clinical trials of a new drug in the United States. The IND includes data from laboratory and preclinical studies, as well as information about how the drug will be studied in people.

FluoGuide stated that FG001 is a clinical-stage product and that significant portions of the submitted IND package, including the preclinical section, are expected to form the basis of a future new drug application, or NDA. An NDA is required to obtain approval to market a drug in the U.S.

Through the pre-IND and IND processes, the company engaged with the FDA to review a comprehensive development package. This included completed work and proposed plans for ongoing and future studies.

Importantly, the company reported that it received FDA alignment on the design of its U.S. phase 2 clinical trial in high-grade glioma to support registration. It also received alignment on key elements of a subsequent phase 3 program. This regulatory agreement on trial design is intended to support a clearer path toward a future NDA submission.

Trial details: phase 2 and phase 3 plans in high-grade glioma

Following the FDA clearance, FluoGuide will continue preparations to initiate its planned U.S. phase 2 registration trial of FG001 in patients with high-grade glioma. The first patient is planned to enroll in the second quarter of 2026.

The company anticipates that two U.S. clinical trials will be required to support U.S. regulatory approval of FG001 for high-grade glioma. Both trials are expected to enroll patients over approximately one year. Final timelines and enrollment numbers may be influenced by emerging data and regulatory feedback as the program moves forward.

The company described this development plan as establishing a structured path toward U.S. approval of FG001 in high-grade glioma. For patients with cancer, this means that the treatment will now be studied in a U.S. clinical setting designed specifically to support potential registration and approval.

FG001 is intended to improve surgical precision by lighting up cancer during surgery. According to the company, improved precision may reduce the frequency of local recurrence after surgery and lessen surgical sequelae. The goal is to increase the likelihood of complete cure and reduce health care costs.

FluoGuide also stated that FG001 has demonstrated effectiveness and has been well tolerated in several phase 2 clinical trials. In addition to high-grade glioma, the lead indications for FG001 include aggressive brain cancer and oral head and neck cancer.

Safety: what is known so far about side effects

In its announcement, FluoGuide stated that FG001 has been well tolerated in several phase 2 clinical trials. However, specific details about side effects were not provided in the release.

As the U.S. phase 2 registration trial begins, researchers will continue to evaluate the safety profile of FG001 in patients with high-grade glioma. Clinical trials are designed to closely monitor side effects, assess how well a treatment works and determine whether the benefits outweigh the risks.

Enrollment for the first U.S. patient in this program is expected in the second quarter of 2026, with additional updates to be provided by the company as appropriate.

References

1. “FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track” FluoGuide A/S. News release.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI and reviewed by a human editor.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.